Monday, September 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

TG Therapeutics Short Interest Declines Indicating Potential Shift in Market Sentiment

Elaine Mendonca by Elaine Mendonca
January 19, 2024
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

TG Therapeutics (NYSE:TGTX) has experienced a notable decline in its short interest, with the percentage of float falling by 12.86% since the previous report. As of January 19, 2024, the company reported 31.83 million shares sold short, which accounts for 25.88% of all regular shares available for trading. This suggests that traders are exhibiting less bearishness towards the stock. The current short interest ratio stands at 5.0, indicating a moderate level of pessimism.

Understanding short interest is crucial as it provides insights into market sentiment surrounding a specific stock. An increase in short interest typically signifies bearishness, while a decrease can indicate bullishness. Nevertheless, it is important to note that a decline in short interest does not guarantee an immediate rise in the stock’s value.

When comparing TG Therapeutics’s short interest to its peers, the company’s average short interest as a percentage of float is reported to be 15.13% by Benzinga Pro.

In conclusion, the decrease in TG Therapeutics’s short interest may suggest a shift in market sentiment towards the stock. However, it is crucial to consider other factors before making any investment decisions.

TG Therapeutics Inc. (TGTX) Sees Mixed Performance on January 19, 2024

TG Therapeutics Inc. (TGTX) experienced a mixed performance on January 19, 2024. The price of TGTX shares decreased by $0.07, marking a 0.46% drop from the previous market close. The stock closed at $15.07 but saw a slight increase of $0.03 in after-hours trading.

TGTX’s current trading position near the lower end of its 52-week range suggests that investors may perceive the stock as undervalued. However, it is important to note that the stock’s performance should be evaluated in conjunction with other fundamental and technical indicators to gain a comprehensive understanding of its investment potential.

Additionally, the fact that TGTX is trading below its 200-day simple moving average indicates a potential bearish sentiment in the market. When a stock is trading below this moving average, it suggests that the overall trend may be downward.

It is worth mentioning that the price change of $0.03 in after-hours trading may not have a significant impact on the overall performance of TGTX. After-hours trading refers to the buying and selling of stocks outside the regular trading hours of the stock market. The volume and liquidity during this period are typically lower compared to regular market hours, which can result in more volatile price movements.

Investors should closely monitor TGTX’s performance in the coming days to determine whether the recent price drop and subsequent after-hours increase are indicative of a trend reversal or merely short-term fluctuations. Conducting thorough research, considering the company’s financials, and consulting with a financial advisor can help investors make informed decisions regarding TGTX and their investment strategies.

TG Therapeutics Inc. (TGTX) Shows Mixed Performance with Significant Revenue Changes: A Path Towards Profitability

TG Therapeutics Inc. (TGTX) has shown mixed performance in its stock prices on January 19, 2024. The company’s total revenue has experienced significant changes over the past year and quarter. TGTX reported a total revenue of $2.79 million over the past year, representing a 58.36% decrease compared to the previous year. However, the company’s total revenue experienced a substantial 931.57% increase since the last quarter, reaching $165.81 million. TGTX reported a net loss of -$198.34 million over the past year, but the net income has increased by 43.02% compared to the previous year. In the third quarter of 2023, TGTX reported a net income of $113.93 million, indicating a remarkable 339.3% increase since the previous quarter. TGTX reported an EPS of -$1.46 over the past year, representing a loss per share. However, the company has improved its EPS by 44.37% compared to the previous year. In the third quarter of 2023, TGTX reported an EPS of $0.73, indicating a significant increase of 317.21% since the previous quarter. These positive trends suggest that TGTX has made significant strides in improving its financial performance and may be on a path towards profitability.

Tags: TGTX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Technology Robotics Trading online

Datasea Inc Implements Reverse Stock Split to Meet Nasdaq Listing Requirements

MMM stock news

Resumption of Trading for Arena Group Holdings Shares

Alternative Energy Markets and money (1)

Options Market Activity for Diamondback Energy Bullish vs Bearish Sentiment

Recommended

First Horizon National Stock

Diverging Views Shape First Horizon National’s Investment Narrative

4 weeks ago
Northern Stock

Strategic Moves: Northern Corporation Adjusts Rates and Expands Global Footprint

2 days ago
CME stock news

Navigating Uncertainty: Analysts Provide Mixed Recommendations for Getinge AB amidst Market Volatility

2 years ago
Automotive Stock Market Today

Wealthy Investors Show Negative Outlook on General Motors NYSE GM

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir PayPal Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Kratos Defense Secures Coveted Spot in S&P MidCap 400 Index

American Express Doubles Down on Premium Market Strategy

Snowflake Gains Momentum with Leadership Shift and Strategic Alliances

Porsche Holding Faces Perfect Storm as Strategic Shifts and Market Pressures Mount

Replimune Shares Plummet Amid Regulatory Crisis and Mounting Litigation

Dividend Growth and Geopolitical Strain: The Texas Instruments Dilemma

Trending

Anavex Stock
Analysis

Anavex Alzheimer’s Drug: Breakthrough Data Meets Market Skepticism

by Dieter Jaworski
September 22, 2025
0

A clinical-stage biopharmaceutical company has generated significant discussion in Alzheimer's research circles with trial results suggesting unprecedented...

Marsh McLennan Stock

Marsh McLennan Appoints New Leader to Drive International Expansion Strategy

September 22, 2025
Polestar Auto.adr/a Stock

Polestar Faces Mounting Challenges as Recall Compounds Financial Woes

September 22, 2025
Kratos Defense Stock

Kratos Defense Secures Coveted Spot in S&P MidCap 400 Index

September 22, 2025
American Express Stock

American Express Doubles Down on Premium Market Strategy

September 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Anavex Alzheimer’s Drug: Breakthrough Data Meets Market Skepticism
  • Marsh McLennan Appoints New Leader to Drive International Expansion Strategy
  • Polestar Faces Mounting Challenges as Recall Compounds Financial Woes

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com